Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
December 20, 2018
While many medical interventions—from vaccines, anesthesia, antibiotics, and even eyeglasses—have initially seemed like playing god, interventions to manipulate directly the heritable genetic endowment fundamental not only to what makes us human, but to what makes each of us unique, had never been seen before.
November 15, 2018
Stephen Ezell gave the keynote presentation at the Life Sciences Tennessee Annual Conference on innovation economics and how smart public policies can stimulate Tennessee’s growing life-sciences innovation sector.
November 10, 2018
As Rob Atkinson writes for The Hill, price controls and other steps to reduce drug company revenues would stifle knowledge generation and sharing, leaving future generations less access to effective new drugs than would otherwise be the case.
November 5, 2018
A considerable share of biopharma research “spills over” and contributes to knowledge discovery and drug development overall, not just in individual firms’ labs.
September 24, 2018
Petition to the Food and Drug Administration Requesting a Stop to Deceptive and Misleading “Non-GMO” Food Labels
The Non-GMO Project food label deliberately deceives and misleads consumers in violation of the Federal Food, Drug and Cosmetic Act. ITIF petitions FDA to prohibit such labels.
September 13, 2018
ITIF's Center for Data Innovation will host a public forum with key stakeholders from government, the private sector, and academia to discuss the latest developments in using data to improve health care outcomes, reduce health care costs, and empower patients.
September 4, 2018
Debates over high-priced prescription drugs tend to focus on whether the government should attempt to constrict the pharmaceutical industry, whether by reducing patent protections or by mandating lower prices. What these conversations miss, though, is that drug prices could also fall through the expansion of the pharmaceutical industry, rather than its restriction.
August 24, 2018
A contagion of poor public policy is sweeping across Latin America in the form of the spreading use of compulsory licenses on novel pharmaceutical drugs, and it threatens to undermine the very ecosystem supporting the development of medicines designed to treat deadly diseases in the first place.
July 30, 2018
Fact of the Week: The Cost To Sequence a Human Genome Decreased More than 99.999 Percent Between 2000 and 2016
The future of medicine lies in better understanding the human genome and how our bodies function at the most basic level, and that requires reliable and inexpensive genome sequencing. Technological breakthroughs, such as fluorescent labelling and programs capable of reconstructing smaller DNA fragments, massively decreased costs of a full genome sequence to from $300 million in 2000 to $1,500 in 2016.
June 28, 2018
As ITIF’s Stephen Ezell and Richard Owens of the Macdonald Laurier Institute write for the Financial Post, free-riding on drug prices is an example of how Canada refuses to step up to what is required for a globally leading innovation culture.